EUVIMEDEUVIMED entdecken
Crossref

PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival

Ourania Parra iD, Weijie Ma, Zhongze Li, Bryan N Coffing, Konstantinos Linos iD, Robert E LeBlanc iD, Shabnam Momtahen iD, Aravindhan Sriharan, Jeffrey M Cloutier, Wendy A Wells, Shaofeng Yan iD

Journal of Cutaneous Pathology · 2023

DOI: 10.1111/cup.14495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cutaneous Pathology, 2023. Verfasst von Ourania Parra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Nevus. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunohistochemistry‐based protein biomarkers can provide useful prognostic information in cutaneous melanoma. The independent prognostic value of Ki‐67 has been studied with variable results. PReferentially expressed Antigen in MElanoma (PRAME) immunohistochemistry is a useful new ancillary tool for distinguishing cutaneous nevi from melanoma; however, its prognostic value has not been well studied. We evaluated PRAME as a prognostic marker in cutaneous melanoma, compared to Ki‐67.

Methods

We analyzed the immunohistochemical expression of PRAME and Ki‐67 in 165 melanocytic lesions, including 92 primary melanomas, 19 metastatic melanomas, and 54 melanocytic nevi using tissue microarrays. PRAME immunostaining was scored based on the percentage of positive nuclei: 0 75%. The percentage of Ki‐67‐positive tumor nuclei was used to calculate the proliferation index.

Results

PRAME and Ki‐67 both showed significantly increased expression in melanomas compared to nevi ( p < 0.0001 and p < 0.001, respectively). There was no significant difference in PRAME expression in primary versus metastatic melanomas. By contrast, the Ki‐67 proliferation index was higher in metastatic melanoma than in primary melanoma ( p = 0.013). Increased Ki‐67 index correlated with ulceration ( p < 0.001), increased Breslow depth ( p = 0.001), and higher mitotic rate ( p < 0.0001), whereas increased PRAME expression correlated with higher mitotic rate ( p = 0.047) and Ki‐67 index ( p = 0.007). Increased Ki‐67 index correlated with worse disease‐specific survival in patients with primary melanoma ( p < 0.001), but PRAME expression did not show prognostic significance in disease‐specific survival ( p = 0.63). In a multivariable analysis of patients with primary melanoma, tumor Breslow depth, ulceration, mitotic rate, and Ki‐67 index were each independent predictors of disease‐specific survival ( p = 0.006, 0.02, 0.001, and 0.04, respectively); however, PRAME expression was not predictive of disease‐specific survival ( p = 0.64).

Conclusion

Ki‐67 is an independent prognostic marker; although increased PRAME expression correlates with the Ki‐67 proliferation index and mitotic rate, PRAME is not an independent prognostic marker for cutaneous melanoma. PRAME and Ki‐67 are useful ancillary tools for distinguishing benign from malignant melanocytic lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsNevusHumansKi-67 AntigenBiomarkers, TumorAntigens, NeoplasmCutaneous Malignant Melanoma

Stichwörter der Autor:innen

Ki-67PRAMEbenign nevuscutaneous malignant melanomaprognosissurvivaltissue microarray

Substanzen

Ki-67 AntigenBiomarkers, TumorAntigens, NeoplasmPRAME protein, human

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
  • Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, USA.
  • Department of Biostatistics, SABER, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.
  • Metropolitan Pathologists, Lakewood, Colorado, USA.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

ORCID-Profile: Ourania Parra, Konstantinos Linos, Robert E LeBlanc, Shabnam Momtahen, Shaofeng Yan

Zitieren

APA

Parra, O., Ma, W., Li, Z., Coffing, B. N., Linos, K., LeBlanc, R. E., Momtahen, S., Sriharan, A., Cloutier, J. M., Wells, W. A., & Yan, S. (2023). PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival. Journal of Cutaneous Pathology. https://doi.org/10.1111/cup.14495

Vancouver

Parra O, Ma W, Li Z, Coffing BN, Linos K, LeBlanc RE, et al. PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival. Journal of Cutaneous Pathology. 2023. doi:10.1111/cup.14495

BibTeX
@article{Parra2023,
  author = {Parra, Ourania and Ma, Weijie and Li, Zhongze and Coffing, Bryan N and Linos, Konstantinos and LeBlanc, Robert E and Momtahen, Shabnam and Sriharan, Aravindhan and Cloutier, Jeffrey M and Wells, Wendy A and Yan, Shaofeng},
  title = {PRAME expression in cutaneous melanoma does not correlate with disease‐specific survival},
  journal = {Journal of Cutaneous Pathology},
  year = {2023},
  doi = {10.1111/cup.14495}
}
Kostenlos starten →